Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer Recurrence

Greenwich LifeSciences Inc GLSI presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery.
Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Final safety conclusions are that GP2 immunotherapy is well tolerated and that no serious adverse events related to GP2 immunotherapy were reported over the full five-year follow-up period.
Data shows 100% disease-free survival (0% recurrence rate) in HER2-positive breast cancer patients over a median of 5 years.
This time series highlights that the 10 GP2 immunotherapy injections over the first 2.5 years created a potent immune response that peaked at six months.
The majority of patients experienced mild or moderate injection site reactions, which accounted for approximately 70% of reported adverse events.
Price Action: GLSI shares are down 2.94% at $37.9 during the market session on the last check Monday.